Revance therapeutics daxxify launch date?

When did Daxxify launch (start sales) after Revance’s approval?

Revance’s Daxxify (daxibotulinumtoxinA-lanm) was approved by the U.S. FDA in September 2022, but the provided sources do not state the specific U.S. commercial launch date (the first date it began routine sales/availability). [1][2]

What timing details are available from FDA approval vs. availability?

The timeline that is confirmed is FDA approval in September 2022. After approval, companies can take additional time for manufacturing ramp-up, distribution, and readiness of prescribing/administrative channels; those “go-live” details are not included in the provided information. [1][2]

What’s the most precise date you can cite from the available info?

You can cite the FDA approval month/year: September 2022. The exact “launch date” (day/month when product became commercially available) is not provided in the supplied material. [1][2]

Sources:
[1] https://www.fda.gov/news-events/press-announcements/fda-approves-daxxify-daxibotulinumtoxina-lanm-treatment-adults
[2] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215854